# Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy

> **NCT01237262** · PHASE4 · UNKNOWN · sponsor: **University of Padova** · enrollment: 20 (estimated)

## Conditions studied

- Moderate to Severe Psoriasis.
- Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.

## Interventions

- **DRUG:** Adalimumab, etanercept, infliximab

## Key facts

- **NCT ID:** NCT01237262
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237262, "Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01237262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*